Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cardiovascular Translational Research
Published in: Journal of Cardiovascular Translational Research 5/2010

01-10-2010

Protein Therapeutics for Cardiac Regeneration after Myocardial Infarction

Authors: Vincent F. M. Segers, Richard T. Lee

Published in: Journal of Cardiovascular Translational Research | Issue 5/2010

Login to get access

Abstract

Although most medicines have historically been small molecules, many newly approved drugs are derived from proteins. Protein therapies have been developed for treatment of diseases in almost every organ system, including the heart. Great excitement has now arisen in the field of regenerative medicine, particularly for cardiac regeneration after myocardial infarction. Every year, millions of people suffer from acute myocardial infarction, but the adult mammalian myocardium has limited regeneration potential. Regeneration of the heart after myocardium infarction is therefore an exciting target for protein therapeutics. In this review, we discuss different classes of proteins that have therapeutic potential to regenerate the heart after myocardial infarction. Protein candidates have been described that induce angiogenesis, including fibroblast growth factors and vascular endothelial growth factors, although thus far clinical development has been disappointing. Chemotactic factors that attract stem cells, e.g., hepatocyte growth factor and stromal cell-derived factor-1, may also be useful. Finally, neuregulins and periostin are proteins that induce cell-cycle reentry of cardiomyocytes, and growth factors like IGF-1 can induce growth and differentiation of stem cells. As our knowledge of the biology of regenerative processes and the role of specific proteins in these processes increases, the use of proteins as regenerative drugs could develop as a cardiac therapy.
Literature
1.
Mathers, C. D., & Loncar, D. (2006). Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine, 3, e442.CrossRefPubMed
2.
3.
4.
Scott, D. W., & De Groot, A. S. (2010). Can we prevent immunogenicity of human protein drugs? Annals of the Rheumatic Diseases, 69, i72–i76.CrossRefPubMed
5.
Solá, R. J., & Griebenow, K. (2009). Effects of glycosylation on the stability of protein pharmaceuticals. Journal of Pharmaceutical Sciences, 98, 1223–1245.CrossRefPubMed
6.
Banai, S., Jaklitsch, M., Casscells, W., Shou, M., Shrivastav, S., Correa, R., et al. (1991). Effects of acidic fibroblast growth factor on normal and ischemic myocardium. Circulation Research, 69, 76–85.PubMed
7.
Pearlman, J. D., Hibberd, M. G., Chuang, M. L., Harada, K., Lopez, J. J., Gladstone, S. R., et al. (1995). Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Natural Medicines, 1, 1085–1089.CrossRef
8.
van der Laan, A. M., Piek, J. J., & van Royen, N. (2009). Targeting angiogenesis to restore the microcirculation after reperfused MI. Nature Reviews Cardiology, 6, 515–523.CrossRefPubMed
9.
Carmeliet, P. (2005). VEGF as a key mediator of angiogenesis in cancer. Oncology, 69(Suppl 3), 4–10.CrossRefPubMed
10.
Yanagisawa-Miwa, A., Uchida, Y., Nakamura, F., Tomaru, T., Kido, H., Kamijo, T., et al. (1992). Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science, 257, 1401–1403.CrossRefPubMed
11.
Epstein, S. E., Kornowski, R., Fuchs, S., & Dvorak, H. F. (2001). Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects. Circulation, 104, 115–119.PubMed
12.
Henry, T. D., Rocha-Singh, K., Isner, J. M., Kereiakes, D. J., Giordano, F. J., Simons, M., et al. (2001). Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. American Heart Journal, 142, 872–880.CrossRefPubMed
13.
Henry, T. D., Annex, B. H., McKendall, G. R., Azrin, M. A., Lopez, J. J., Giordano, F. J., et al. (2003). The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation, 107, 1359–1365.CrossRefPubMed
14.
Lee, R. J., Springer, M. L., Blanco-Bose, W. E., Shaw, R., Ursell, P. C., & Blau, H. M. (2000). VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation, 102, 898–901.PubMed
15.
Dulak, J., Zagorska, A., Wegiel, B., Loboda, A., & Jozkowicz, A. (2006). New strategies for cardiovascular gene therapy. Cell Biochemistry and Biophysics, 44, 31–42.CrossRefPubMed
16.
London, N., Whitehead, K., & Li, D. (2009). Endogenous endothelial cell signaling systems maintain vascular stability. Angiogenesis, 12, 149–158.CrossRefPubMed
17.
Byrne, A. M., Bouchier-Hayes, D. J., & Harmey, J. H. (2005). Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF). Journal of Cellular and Molecular Medicine, 9, 777–794.CrossRefPubMed
18.
19.
Scott, R. C., Rosano, J. M., Ivanov, Z., Wang, B., Chong, P. L.-G., Issekutz, A. C., et al. (2009). Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function. The FASEB Journal, 23, 3361–3367.CrossRefPubMed
20.
Beltrami, A. P., Barlucchi, L., Torella, D., Baker, M., Limana, F., Chimenti, S., et al. (2003). Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell, 114, 763–776.CrossRefPubMed
21.
Oh, H., Bradfute, S. B., Gallardo, T. D., Nakamura, T., Gaussin, V., Mishina, Y., et al. (2003). Cardiac progenitor cells from adult myocardium: Homing, differentiation, and fusion after infarction. Proceedings of the National Academy of Sciences of the United States of America, 100, 12313–12318.CrossRefPubMed
22.
Mouquet, F., Pfister, O., Jain, M., Oikonomopoulos, A., Ngoy, S., Summer, R., et al. (2005). Restoration of cardiac progenitor cells after myocardial infarction by self-proliferation and selective homing of bone marrow-derived stem cells. Circulation Research, 97, 1090–1092.CrossRefPubMed
23.
Hsieh, P. C., Segers, V. F., Davis, M. E., MacGillivray, C., Gannon, J., Molkentin, J. D., et al. (2007). Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Natural Medicines, 13, 970–974.CrossRef
24.
Orlic, D., Kajstura, J., Chimenti, S., Limana, F., Jakoniuk, I., Quaini, F., et al. (2001). Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proceedings of the National Academy of Sciences of the United States of America, 98, 10344–10349.CrossRefPubMed
25.
Ince, H., Petzsch, M., Kleine, H. D., Eckard, H., Rehders, T., Burska, D., et al. (2005). Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: Final 1-year results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colony-Stimulating Factor (FIRSTLINE-AMI) Trial. Circulation, 112, I-73–I-80.CrossRef
26.
Engelmann, M. G., Theiss, H. D., Hennig-Theiss, C., Huber, A., Wintersperger, B. J., Werle-Ruedinger, A.-E., et al. (2006). Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: Final results from the G-CSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. Journal of the American College of Cardiology, 48, 1712–1721.CrossRefPubMed
27.
Abdel-Latif, A., Bolli, R., Zuba-Surma, E. K., Tleyjeh, I. M., Hornung, C. A., & Dawn, B. (2008). Granulocyte colony-stimulating factor therapy for cardiac repair after acute myocardial infarction: A systematic review and meta-analysis of randomized controlled trials. American Heart Journal, 156, 216–226. e219.CrossRefPubMed
28.
Harada, M., Qin, Y., Takano, H., Minamino, T., Zou, Y., Toko, H., et al. (2005). G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Natural Medicines, 11, 305–311.CrossRef
29.
Nakamura, T., Nishizawa, T., Hagiya, M., Seki, T., Shimonishi, M., Sugimura, A., et al. (1989). Molecular cloning and expression of human hepatocyte growth factor. Nature, 342, 440–443.CrossRefPubMed
30.
Boros, P., & Miller, C. M. (1995). Hepatocyte growth factor: a multifunctional cytokine. Lancet, 345, 293–295.CrossRefPubMed
31.
Nakamura, T., Mizuno, S., Matsumoto, K., Sawa, Y., Matsuda, H., & Nakamura, T. (2000). Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. The Journal of Clinical Investigation, 106, 1511–1519.CrossRefPubMed
32.
Urbanek, K., Rota, M., Cascapera, S., Bearzi, C., Nascimbene, A., De Angelis, A., et al. (2005). Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circulation Research, 97, 663–673.CrossRefPubMed
33.
Wang, Y., Ahmad, N., Wani, M. A., & Ashraf, M. (2004). Hepatocyte growth factor prevents ventricular remodeling and dysfunction in mice via Akt pathway and angiogenesis. Journal of Molecular and Cellular Cardiology, 37, 1041–1052.CrossRefPubMed
34.
Aiuti, A., Webb, I. J., Bleul, C., Springer, T., & Gutierrez-Ramos, J. C. (1997). The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. The Journal of Experimental Medicine, 185, 111–120.CrossRefPubMed
35.
Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa, S., Kitamura, Y., et al. (1996). Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature, 382, 635–638.CrossRefPubMed
36.
Zou, Y.-R., Kottmann, A. H., Kuroda, M., Taniuchi, I., & Littman, D. R. (1998). Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature, 393, 595–599.CrossRefPubMed
37.
J-i, Y., Kusano, K. F., Masuo, O., Kawamoto, A., Silver, M., Murasawa, S., et al. (2003). Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation, 107, 1322–1328.CrossRef
38.
Pillarisetti, K., & Gupta, S. (2001). Cloning and relative expression analysis of rat stromal cell derived factor-1 (SDF-1): SDF-1 α mRNA is selectively induced in rat model of myocardial infarction. Inflammation, 25, 293–300.CrossRefPubMed
39.
Askari, A. T., Unzek, S., Popovic, Z. B., Goldman, C. K., Forudi, F., Kiedrowski, M., et al. (2003). Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet, 362, 697–703.CrossRefPubMed
40.
McQuibban, G. A., Butler, G. S., Gong, J. H., Bendall, L., Power, C., Clark-Lewis, I., et al. (2001). Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. The Journal of Biological Chemistry, 276, 43503–43508.CrossRefPubMed
41.
Segers, V. F., Tokunou, T., Higgins, L. J., MacGillivray, C., Gannon, J., & Lee, R. T. (2007). Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation, 116, 1683–1692.CrossRefPubMed
42.
Schenk, S., Mal, N., Finan, A., Zhang, M., Kiedrowski, M., Popovic, Z., et al. (2007). Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells, 25, 245–251.CrossRefPubMed
43.
Bergmann, O., Bhardwaj, R. D., Bernard, S., Zdunek, S., Barnabe-Heider, F., Walsh, S., et al. (2009). Evidence for cardiomyocyte renewal in humans. Science, 324, 98–102.CrossRefPubMed
44.
Murry, C. E., & Lee, R. T. (2009). Development biology. Turnover after the fallout. Science, 324, 47–48.CrossRefPubMed
45.
Borchardt, T., & Braun, T. (2007). Cardiovascular regeneration in non-mammalian model systems: What are the differences between newts and man? Thrombosis and Haemostasis, 98, 311–318.PubMed
46.
Poss, K. D. (2007). Getting to the heart of regeneration in zebrafish. Seminars in Cell & Developmental Biology, 18, 36–45.CrossRef
47.
Kuhn, B., del Monte, F., Hajjar, R. J., Chang, Y.-S., Lebeche, D., Arab, S., et al. (2007). Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Natural Medicines, 13, 962–969.CrossRef
48.
Bersell, K., Arab, S., Haring, B., & Kühn, B. (2009). Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell, 138, 257–270.CrossRefPubMed
49.
Yan, W., & Shao, R. (2006). Transduction of a Mesenchyme-specific gene periostin into 293 T cells induces cell invasive activity through epithelial-mesenchymal transformation. The Journal of Biological Chemistry, 281, 19700–19708.CrossRefPubMed
50.
Butcher, J. T., Norris, R. A., Hoffman, S., Mjaatvedt, C. H., & Markwald, R. R. (2007). Periostin promotes atrioventricular mesenchyme matrix invasion and remodeling mediated by integrin signaling through Rho/PI 3-kinase. Developmental Biology, 302, 256–266.CrossRefPubMed
51.
Conway, S. J., & Molkentin, J. D. (2008). Periostin as a heterofunctional regulator of cardiac development and disease. Current Genomics, 9, 548–555.CrossRefPubMed
52.
Oka, T., Xu, J., Kaiser, R. A., Melendez, J., Hambleton, M., Sargent, M. A., et al. (2007). Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circulation Research, 101, 313–321.CrossRefPubMed
53.
Lorts, A., Schwanekamp, J. A., Elrod, J. W., Sargent, M. A., & Molkentin, J. D. (2009). Genetic manipulation of periostin expression in the heart does not affect myocyte content, cell cycle activity, or cardiac repair. Circulation Research, 104, e1–e7.CrossRefPubMed
54.
Lemmens, K., Doggen, K., & De Keulenaer, G. W. (2007). Role of Neuregulin-1/ErbB signaling in cardiovascular physiology and disease: Implications for therapy of heart failure. Circulation, 116, 954–960.CrossRefPubMed
55.
Lemmens, K., Segers, V. F. M., Demolder, M., & De Keulenaer, G. W. (2006). Role of Neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk. The Journal of Biological Chemistry, 281, 19469–19477.CrossRefPubMed
56.
Mourkioti, F., & Rosenthal, N. (2005). IGF-1, inflammation and stem cells: Interactions during muscle regeneration. Trends in Immunology, 26, 535–542.CrossRefPubMed
57.
Fazio, S., Palmieri, E., Biondi, B., Cittadini, A., & Sacca, L. (2000). The role of the GH-IGF-I axis in the regulation of myocardial growth: from experimental models to human evidence. European Journal of Endocrinology, 142, 211–216.CrossRefPubMed
58.
Padin-Iruegas, M. E., Misao, Y., Davis, M. E., Segers, V. F., Esposito, G., Tokunou, T., et al. (2009). Cardiac progenitor cells and biotinylated insulin-like growth factor-1 nanofibers improve endogenous and exogenous myocardial regeneration after infarction. Circulation, 120, 876–887.CrossRefPubMed
59.
Rota, M., Padin-Iruegas, M. E., Misao, Y., De Angelis, A., Maestroni, S., Ferreira-Martins, J., et al. (2008). Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function. Circulation Research, 103, 107–116.CrossRefPubMed
60.
Tulloch, N. L., Pabon, L., & Murry, C. E. (2008). Get with the (Re)program: Cardiovascular potential of skin-derived induced pluripotent stem cells. Circulation, 118, 472–475.CrossRefPubMed
61.
Mauritz, C., Schwanke, K., Reppel, M., Neef, S., Katsirntaki, K., Maier, L. S., et al. (2008). Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation, 118, 507–517.CrossRefPubMed
62.
Narazaki, G., Uosaki, H., Teranishi, M., Okita, K., Kim, B., Matsuoka, S., et al. (2008). Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation, 118, 498–506.CrossRefPubMed
63.
Filipczyk, A., Passier, R., Rochat, A., & Mummery, C. (2007). Cardiovascular development: Towards biomedical applicability. Cellular and Molecular Life Sciences, 64, 704–718.CrossRefPubMed
64.
Klocke, R., Kuhlmann, M. T., Scobioala, S., Schabitz, W. R., & Nikol, S. (2008). Granulocyte colony-stimulating factor (G-CSF) for cardio- and cerebrovascular regenerative applications. Current Medicinal Chemistry, 15, 968–977.CrossRefPubMed
65.
Kang, J. S., DeLuca, P. P., & Lee, K. C. (2009). Emerging PEGylated drugs. Expert Opinion on Emerging Drugs, 14, 363–380.CrossRefPubMed
66.
Obana, M., Maeda, M., Takeda, K., Hayama, A., Mohri, T., Yamashita, T., et al. (2010). Therapeutic activation of signal transducer and activator of transcription 3 by Interleukin-11 ameliorates cardiac fibrosis after myocardial infarction. Circulation, 121, 684–691.CrossRefPubMed
67.
Seki, K., Sanada, S., Kudinova, A. Y., Steinhauser, M. L., Handa, V., Gannon, J., et al. (2009). Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail, 2, 684–691.CrossRefPubMed
68.
Kondo, K., Shibata, R., Unno, K., Shimano, M., Ishii, M., Tetsutaro, K., et al. (2010). Impact of a single intracoronary administration of adiponectin on myocardial ischemia/reperfusion injury in a pig model. Circ Cardiovasc Interv, 3(2), 166–173.CrossRefPubMed
69.
Bock-Marquette, I., Saxena, A., White, M. D., Michael DiMaio, J., & Srivastava, D. (2004). Thymosin [beta]4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 432, 466–472.CrossRefPubMed
70.
Sasaki, T., Fukazawa, R., Ogawa, S., Kanno, S., Nitta, T., Ochi, M., et al. (2007). Stromal cell-derived factor-1; improves infarcted heart function through angiogenesis in mice. Pediatrics International, 49, 966–971.CrossRefPubMed
71.
Saxena, A., Fish, J. E., White, M. D., Yu, S., Smyth, J. W. P., Shaw, R. M., et al. (2008). Stromal cell-derived factor-1{alpha} is cardioprotective after myocardial infarction. Circulation, 117, 2224–2231.CrossRefPubMed
72.
Hsieh, P. C. H., Davis, M. E., Gannon, J., MacGillivray, C., & Lee, R. T. (2006). Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. The Journal of Clinical Investigation, 116, 237–248.CrossRefPubMed
73.
Zaruba, M.-M., Huber, B. C., Brunner, S., Deindl, E., David, R., Fischer, R., et al. (2008). Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival. Cardiovascular Research, 77, 722–731.CrossRefPubMed
74.
Sugano, Y., Anzai, T., Yoshikawa, T., Maekawa, Y., Kohno, T., Mahara, K., et al. (2005). Granulocyte colony-stimulating factor attenuates early ventricular expansion after experimental myocardial infarction. Cardiovascular Research, 65, 446–456.CrossRefPubMed
75.
Hasegawa, H., Takano, H., Iwanaga, K., Ohtsuka, M., Qin, Y., Niitsuma, Y., et al. (2006). Cardioprotective effects of granulocyte colony-stimulating factor in swine with chronic myocardial ischemia. Journal of the American College of Cardiology, 47, 842–849.CrossRefPubMed
76.
van der Meer, P., Lipsic, E., Henning, R. H., Boddeus, K., van der Velden, J., Voors, A. A., et al. (2005). Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. Journal of the American College of Cardiology, 46, 125–133.CrossRefPubMed
77.
Battler, A., Scheinowitz, M., Bor, A., Hasdai, D., Vered, Z., Di Segni, E., et al. (1993). Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. Journal of the American College of Cardiology, 22, 2001–2006.CrossRefPubMed
Metadata
Title
Protein Therapeutics for Cardiac Regeneration after Myocardial Infarction
Authors
Vincent F. M. Segers
Richard T. Lee
Publication date
01-10-2010
Publisher
Springer US
Published in
Journal of Cardiovascular Translational Research / Issue 5/2010
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-010-9207-5

Other articles of this Issue 5/2010

Journal of Cardiovascular Translational Research 5/2010 Go to the issue

OriginalPaper

Drug Discovery in a Multidimensional World: Systems, Patterns, and Networks

OriginalPaper

Extreme Respiratory Sinus Arrhythmia Enables Overwintering Black Bear Survival—Physiological Insights and Applications to Human Medicine

OriginalPaper

Our Expanding View of Platelet Functions and Its Clinical Implications

OriginalPaper

Development of Hydrogen Sulfide-Based Therapeutics for Cardiovascular Disease

OriginalPaper

Delivering Regenerative Cues to the Heart: Cardiac Drug Delivery by Microspheres and Peptide Nanofibers

OriginalPaper

Cardiovascular Drug Discovery in the Academic Setting: Building Infrastructure, Harnessing Strengths, and Seeking Synergies

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits